Navigation Links
Associated therapy for multiple myeloma

According to a new study it is observed that thalidomide is effective as first-line therapy for newly diagnosed multiple myeloma patients when combined with a standard chemotherapy agent. Researchers from the Mayo Clinic in Rochester, Minn.// gave 60 newly diagnosed myeloma patients the drug thalidomide along with the synthetic steroid dexamethasone. Results show 55 percent of patients responded to the combination. Researchers also observed an improvement in associated symptoms and in disturbances in the blood.

Results also show the thalidomide combination was well tolerated. Researchers say current chemotherapy regimens used as initial therapy for multiple myeloma have significant toxicity. In addition, the thalidomide combination is administered orally while current chemotherapy requires intravenous administration.

Multiple myeloma is a malignant cancer of the plasma cell, which is a type of white blood cell found in many tissues of the body. As the cancer grows, it destroys normal bone tissue, which causes pain and crowds out normal cell production.

Multiple myeloma is the second most common blood cancer in the United States. It remains incurable despite the use of conventional and high dose chemotherapy.


'"/>




Page: 1

Related medicine news :

1. Moderate Use of Analgesics - Not Associated With Kidney Dysfunction
2. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
3. Associated scan for detecting ovarian cancer spread
4. Ginseng Associated with Pregnancy Risks
5. Enzyme Associated with Memory
6. 3 die, 500 sickened in nations largest hepatitis A outbreak Associated Press
7. Enzyme Associated With Memory
8. Problems Associated With Iron Deficiency
9. Asbestos Exposure Associated With An Increased Risk For Autoimmune Disease
10. Young Patients On Antidepressants Found To Be Associated With Suicidal Tendencies
11. Sleepiness May Be Associated With Visual Impairment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology: